Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.30 |
| ▸ | KLK1 | P06870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4099709 | 0.85 | L3MBTL1 (0.45) | L3MBTL1NPC1KDM4EPOLBEGLN1 | |
| SCHEMBL4106191 | 0.82 | L3MBTL1 (0.49) | L3MBTL1NPC1KDM4E | |
| SCHEMBL4110150 | 0.81 | L3MBTL1 (0.49) | L3MBTL1KDM4EPOLB | |
| SCHEMBL4104664 | 0.67 | P2RY12 (0.34) | L3MBTL1NPC1KDM4E | |
| SCHEMBL4118608 | 0.67 | L3MBTL1 (0.33) | L3MBTL1NPC1KDM4E | |
| SCHEMBL949202 | 0.65 | TSHR (0.39) | NPC1KDM4EPOLB | |
| SCHEMBL23163199 | 0.64 | SMN1; SMN2 (0.41) | NPC1KDM4E | |
| SCHEMBL5592406 | 0.64 | KMT2A (0.37) | L3MBTL1KDM4EPOLB | |
| SCHEMBL4106805 | 0.63 | KMT2A (0.50) | KDM4E | |
| SCHEMBL17796240 | 0.62 | ALDH1A1 (0.34) | NPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227555-A2 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090042852-A1 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| US-20080312208-A1 | Pyridine Analogues | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042852-A1 | Novel Pyridine Compounds | P2RY12, P2RY11, P2RY1 | L3MBTL1 4838/4885NPC1 3171/4885CNR2 41/4885 |
| US-20090227555-A2 | Novel Pyridine Compounds | P2RY12, P2RY1, P2RY11 | L3MBTL1 4877/4885NPC1 3970/4885CNR2 51/4885 |
| US-20080312208-A1 | Pyridine Analogues | P2RY12, P2RY11, P2RY1 | L3MBTL1 4857/4885NPC1 3327/4885CNR2 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.